Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.67
NYSE:MCK's Cash to Debt is ranked higher than
56% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.61 vs. NYSE:MCK: 0.67 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:MCK' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.57 Max: N/A
Current: 0.67
Equity to Asset 0.16
NYSE:MCK's Equity to Asset is ranked lower than
92% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.44 vs. NYSE:MCK: 0.16 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:MCK' s Equity to Asset Range Over the Past 10 Years
Min: 0.15  Med: 0.26 Max: 0.35
Current: 0.16
0.15
0.35
Interest Coverage 9.73
NYSE:MCK's Interest Coverage is ranked lower than
53% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.09 vs. NYSE:MCK: 9.73 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MCK' s Interest Coverage Range Over the Past 10 Years
Min: 7.81  Med: 9.11 Max: 12.77
Current: 9.73
7.81
12.77
F-Score: 6
Z-Score: 4.22
M-Score: -2.53
WACC vs ROIC
7.98%
17.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 1.65
NYSE:MCK's Operating margin (%) is ranked lower than
73% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.02 vs. NYSE:MCK: 1.65 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:MCK' s Operating margin (%) Range Over the Past 10 Years
Min: 1.12  Med: 1.69 Max: 1.89
Current: 1.65
1.12
1.89
Net-margin (%) 0.99
NYSE:MCK's Net-margin (%) is ranked lower than
73% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.85 vs. NYSE:MCK: 0.99 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:MCK' s Net-margin (%) Range Over the Past 10 Years
Min: 0.77  Med: 1.03 Max: 1.18
Current: 0.99
0.77
1.18
ROE (%) 21.13
NYSE:MCK's ROE (%) is ranked higher than
92% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.93 vs. NYSE:MCK: 21.13 )
Ranked among companies with meaningful ROE (%) only.
NYSE:MCK' s ROE (%) Range Over the Past 10 Years
Min: 13.37  Med: 17.09 Max: 26.68
Current: 21.13
13.37
26.68
ROA (%) 3.37
NYSE:MCK's ROA (%) is ranked lower than
52% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.80 vs. NYSE:MCK: 3.37 )
Ranked among companies with meaningful ROA (%) only.
NYSE:MCK' s ROA (%) Range Over the Past 10 Years
Min: 2.79  Med: 4.07 Max: 4.73
Current: 3.37
2.79
4.73
ROC (Joel Greenblatt) (%) 112.92
NYSE:MCK's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.27 vs. NYSE:MCK: 112.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:MCK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 63.18  Med: 118.28 Max: 182.66
Current: 112.92
63.18
182.66
Revenue Growth (3Y)(%) 16.90
NYSE:MCK's Revenue Growth (3Y)(%) is ranked higher than
84% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 7.00 vs. NYSE:MCK: 16.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:MCK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.7  Med: 12.9 Max: 26.5
Current: 16.9
7.7
26.5
EBITDA Growth (3Y)(%) 18.70
NYSE:MCK's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: 8.80 vs. NYSE:MCK: 18.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:MCK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.7  Med: 16.7 Max: 171.6
Current: 18.7
-52.7
171.6
EPS Growth (3Y)(%) 20.00
NYSE:MCK's EPS Growth (3Y)(%) is ranked higher than
65% of the 37 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.30 vs. NYSE:MCK: 20.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:MCK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.2  Med: 13.3 Max: 87.1
Current: 20
7.2
87.1
» NYSE:MCK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MCK Guru Trades in Q4 2015

George Soros 2,100 sh (New)
John Paulson 8,100 sh (New)
Manning & Napier Advisors, Inc 28,820 sh (New)
Jerome Dodson 80,000 sh (New)
Ray Dalio 41,813 sh (+56.53%)
Andreas Halvorsen 2,761,995 sh (+21.45%)
Larry Robbins 2,192,841 sh (+21.13%)
Vanguard Health Care Fund 6,619,780 sh (+2.30%)
Ken Fisher Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
First Pacific Advisors 43,865 sh (-7.47%)
Mario Gabelli 13,925 sh (-21.33%)
Pioneer Investments 237,417 sh (-51.14%)
Scott Black 9,446 sh (-75.33%)
Paul Tudor Jones 2,028 sh (-75.50%)
Joel Greenblatt 46,915 sh (-83.27%)
» More
Q1 2016

MCK Guru Trades in Q1 2016

Wallace Weitz 57,675 sh (New)
Arnold Van Den Berg 70,171 sh (New)
Diamond Hill Capital 1,375 sh (New)
Charles Brandes 42,931 sh (New)
John Buckingham 22,294 sh (New)
Dodge & Cox 2,590 sh (New)
Steven Cohen 9,200 sh (New)
Joel Greenblatt 367,238 sh (+682.77%)
John Paulson 62,500 sh (+671.60%)
First Pacific Advisors 90,250 sh (+105.74%)
Manning & Napier Advisors, Inc 42,880 sh (+48.79%)
Vanguard Health Care Fund 7,165,280 sh (+8.24%)
Jerome Dodson 80,000 sh (unchged)
Andreas Halvorsen Sold Out
George Soros Sold Out
Scott Black 9,313 sh (-1.41%)
Mario Gabelli 12,070 sh (-13.32%)
Paul Tudor Jones 1,434 sh (-29.29%)
Larry Robbins 927,411 sh (-57.71%)
Ray Dalio 13,000 sh (-68.91%)
Pioneer Investments 11,804 sh (-95.03%)
» More
Q2 2016

MCK Guru Trades in Q2 2016

Tom Gayner 9,100 sh (New)
Ronald Muhlenkamp 46,183 sh (New)
Jim Simons 97,400 sh (New)
David Dreman 5,004 sh (New)
Steven Cohen 175,700 sh (+1809.78%)
Ray Dalio 33,359 sh (+156.61%)
Diamond Hill Capital 1,382 sh (+0.51%)
Vanguard Health Care Fund 7,165,280 sh (unchged)
Wallace Weitz 57,675 sh (unchged)
Pioneer Investments Sold Out
Dodge & Cox Sold Out
Larry Robbins Sold Out
Paul Tudor Jones Sold Out
John Buckingham 22,267 sh (-0.12%)
Arnold Van Den Berg 68,913 sh (-1.79%)
Scott Black 9,047 sh (-2.86%)
John Paulson 60,500 sh (-3.20%)
First Pacific Advisors 85,300 sh (-5.48%)
Charles Brandes 39,287 sh (-8.49%)
Manning & Napier Advisors, Inc 36,300 sh (-15.35%)
Jerome Dodson 40,000 sh (-50.00%)
Joel Greenblatt 181,378 sh (-50.61%)
Mario Gabelli 5,000 sh (-58.57%)
» More
Q3 2016

MCK Guru Trades in Q3 2016

Paul Tudor Jones 9,323 sh (New)
Samuel Isaly 193,108 sh (New)
Jim Simons 758,300 sh (+678.54%)
Charles Brandes 55,134 sh (+40.34%)
Joel Greenblatt 235,225 sh (+29.69%)
Manning & Napier Advisors, Inc 45,250 sh (+24.66%)
Ray Dalio 41,359 sh (+23.98%)
John Paulson 67,000 sh (+10.74%)
Wallace Weitz 58,080 sh (+0.70%)
Jerome Dodson 40,000 sh (unchged)
Vanguard Health Care Fund 7,165,280 sh (unchged)
Tom Gayner 9,100 sh (unchged)
David Dreman 5,004 sh (unchged)
Mario Gabelli 5,000 sh (unchged)
Steven Cohen Sold Out
Scott Black 9,035 sh (-0.13%)
John Buckingham 22,140 sh (-0.57%)
Ronald Muhlenkamp 45,753 sh (-0.93%)
Arnold Van Den Berg 67,944 sh (-1.41%)
Diamond Hill Capital 1,360 sh (-1.59%)
First Pacific Advisors 83,080 sh (-2.60%)
» More
» Details

Insider Trades

Latest Guru Trades with MCK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution
Compare:NYSE:CAH, NYSE:ABC, OTCPK:SHTDF, NAS:HSIC, NAS:PDCO, NYSE:PBH, NYSE:OMI, OTCPK:UDHCF, NYSE:PMC, OTCPK:SNYR, OTCPK:NPHC, OTCPK:FZMD, OTCPK:SCVM » details
Traded in other countries:MCK.Germany, MCK.Mexico,
McKesson Corporation distributes pharmaceuticals, medical supplies and healthcare information technology that make healthcare safer while reducing costs.

McKesson Corporation is a Delaware Corporation. The Company delivers pharmaceuticals, medical supplies and healthcare information technology that make healthcare safer while reducing costs. The Company operates in two segments. The McKesson Distribution Solutions segment distributes ethical and proprietary drugs and equipment and health and beauty care products throughout North America and internationally. This segment provides specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, and practice management, technology, clinical support and business solutions to oncology and other specialty practices operating in the community setting. This segment also provides medical-surgical supply distribution, equipment, logistics and other services to healthcare providers through a network of distribution centers within the U.S. In addition, this segment sells financial, operational and clinical solutions for pharmacies (retail, hospital, alternate site) and provides consulting, outsourcing and other services. The McKesson Technology Solutions segment includes McKesson Health Solutions, which includes its InterQual clinical criteria solution, claims payment solutions and network performance tools. This segment also delivers enterprise-wide clinical, patient care, financial, supply chain, strategic management software solutions, as well as connectivity, outsourcing and other services, including remote hosting and managed services, to healthcare organizations. This segment's customers include hospitals, physicians, homecare providers, retail pharmacies and payers from North America. McKesson Distribution Solutions consists of the following businesses: North America pharmaceutical distribution and services, International pharmaceutical distribution and services and Medical Surgical distribution and services. The Company competes with other software services firms, consulting firms, shared service vendors, certain hospitals and hospital groups, payers, care management organizations, hardware vendors and internet-based companies with technology applicable to the healthcare industry.

Guru Investment Theses on McKesson Corp

Mario Gabelli Comments on McKesson Corp - Jul 26, 2016

McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns.

From Mario Gabelli (Trades, Portfolio)'s Gabelli Asset Fund second quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Mario Gabelli Comments on McKesson Corp - Jul 25, 2016

McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns.



From the Gabelli ABC Merger Arbitrage Fund second quarter 2016 shareholder letter.



Check out Mario Gabelli latest stock trades

Parnassus Fund Comments on McKesson - May 09, 2016

McKesson (NYSE:MCK), the largest drug distributor in the nation, sliced 50 basis points from the Fund’s return, as the stock declined 20.3% from $197.23 to $157.25. The stock moved lower after management provided weaker-than-expected guidance due to weaker generic drug prices. McKesson also lost some drugstore customers, as several chains were acquired by firms using other distributors. Despite these headwinds, we expect revenue to recover through organic growth and attracting new customers. McKesson provides significant value to consumers by improving the efficiency of drug procurement and delivery, which we believe will generate shareholder value over the long term.



From the Parnassus Fund first quarter 2016 shareholder letter.



Check out Jerome Dodson latest stock trades

Wallace Weitz Comments on McKesson - Apr 22, 2016

McKesson (NYSE:MCK) distributes drugs, equipment, and health and beauty products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Merger-related customer losses (McKesson accounts Omnicare, Target Pharmacy and Rite Aid are moving to competing wholesalers after being acquired), the return of generic drug deflation and concerns of lower future branded drug inflation combined to drive McKesson’s stock down nearly 40% from its high last summer. Having done detailed work on the company roughly nine years prior, we sharpened our pencils again late last year and initiated a position at $150 in January. The drug wholesaling business is an attractive oligopoly characterized by intense but rational competition, stable growth, healthy returns on capital and consistent excess cash generation. While McKesson’s business faces some near-term headwinds, we believe it is an attractive investment over the long term.

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about McKesson Corp

Sometimes It Is Good to Buy the Biggest. But Should You Buy the Biggest Health Care Distribution Business? McKesson is a giant that has recently experienced a pullback. Does that make it a good prospect, or would its competitors be better opportunities?
Mario Gabelli Comments on McKesson Corp Guru stock highlight
McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns. Read more...
Mario Gabelli Comments on McKesson Corp Gabelli shareholder letter
McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns. Read more...
Parnassus Fund Comments on McKesson Guru stock highlight
McKesson (NYSE:MCK), the largest drug distributor in the nation, sliced 50 basis points from the Fund’s return, as the stock declined 20.3% from $197.23 to $157.25. The stock moved lower after management provided weaker-than-expected guidance due to weaker generic drug prices. McKesson also lost some drugstore customers, as several chains were acquired by firms using other distributors. Despite these headwinds, we expect revenue to recover through organic growth and attracting new customers. McKesson provides significant value to consumers by improving the efficiency of drug procurement and delivery, which we believe will generate shareholder value over the long term. Read more...
Wallace Weitz Comments on McKesson Guru stock highlight
McKesson (NYSE:MCK) distributes drugs, equipment, and health and beauty products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Merger-related customer losses (McKesson accounts Omnicare, Target Pharmacy and Rite Aid are moving to competing wholesalers after being acquired), the return of generic drug deflation and concerns of lower future branded drug inflation combined to drive McKesson’s stock down nearly 40% from its high last summer. Having done detailed work on the company roughly nine years prior, we sharpened our pencils again late last year and initiated a position at $150 in January. The drug wholesaling business is an attractive oligopoly characterized by intense but rational competition, stable growth, healthy returns on capital and consistent excess cash generation. While McKesson’s business faces some near-term headwinds, we believe it is an attractive investment over the long term. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.31
MCK's P/E(ttm) is ranked higher than
67% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 20.98 vs. MCK: 17.31 )
Ranked among companies with meaningful P/E(ttm) only.
MCK' s P/E(ttm) Range Over the Past 10 Years
Min: 8.17  Med: 18.48 Max: 38.44
Current: 17.31
8.17
38.44
Forward P/E 11.40
MCK's Forward P/E is ranked higher than
80% of the 10 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.68 vs. MCK: 11.40 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.16
MCK's PE(NRI) is ranked higher than
77% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 20.98 vs. MCK: 16.16 )
Ranked among companies with meaningful PE(NRI) only.
MCK' s PE(NRI) Range Over the Past 10 Years
Min: 8.17  Med: 18.24 Max: 33.83
Current: 16.16
8.17
33.83
Price/Owner Earnings (ttm) 7.45
MCK's Price/Owner Earnings (ttm) is ranked higher than
89% of the 28 Companies
in the Global Medical Distribution industry.

( Industry Median: 20.57 vs. MCK: 7.45 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MCK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.5  Med: 12.44 Max: 37.98
Current: 7.45
5.5
37.98
P/B 3.46
MCK's P/B is ranked lower than
82% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.38 vs. MCK: 3.46 )
Ranked among companies with meaningful P/B only.
MCK' s P/B Range Over the Past 10 Years
Min: 1.31  Med: 2.83 Max: 6.98
Current: 3.46
1.31
6.98
P/S 0.17
MCK's P/S is ranked higher than
87% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.89 vs. MCK: 0.17 )
Ranked among companies with meaningful P/S only.
MCK' s P/S Range Over the Past 10 Years
Min: 0.08  Med: 0.19 Max: 0.32
Current: 0.17
0.08
0.32
PFCF 7.04
MCK's PFCF is ranked higher than
87% of the 24 Companies
in the Global Medical Distribution industry.

( Industry Median: 16.35 vs. MCK: 7.04 )
Ranked among companies with meaningful PFCF only.
MCK' s PFCF Range Over the Past 10 Years
Min: 6.07  Med: 12.44 Max: 43.64
Current: 7.04
6.07
43.64
POCF 6.20
MCK's POCF is ranked higher than
83% of the 24 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.25 vs. MCK: 6.20 )
Ranked among companies with meaningful POCF only.
MCK' s POCF Range Over the Past 10 Years
Min: 5.34  Med: 10.4 Max: 98.78
Current: 6.2
5.34
98.78
EV-to-EBIT 10.79
MCK's EV-to-EBIT is ranked higher than
80% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.05 vs. MCK: 10.79 )
Ranked among companies with meaningful EV-to-EBIT only.
MCK' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.7  Med: 11.4 Max: 22.5
Current: 10.79
5.7
22.5
EV-to-EBITDA 8.47
MCK's EV-to-EBITDA is ranked higher than
83% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.07 vs. MCK: 8.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
MCK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.5  Med: 9.3 Max: 16.9
Current: 8.47
4.5
16.9
PEG 0.83
MCK's PEG is ranked higher than
84% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.20 vs. MCK: 0.83 )
Ranked among companies with meaningful PEG only.
MCK' s PEG Range Over the Past 10 Years
Min: 0.16  Med: 1.25 Max: 8.81
Current: 0.83
0.16
8.81
Shiller P/E 25.47
MCK's Shiller P/E is ranked higher than
61% of the 18 Companies
in the Global Medical Distribution industry.

( Industry Median: 28.15 vs. MCK: 25.47 )
Ranked among companies with meaningful Shiller P/E only.
MCK' s Shiller P/E Range Over the Past 10 Years
Min: 14.98  Med: 29.72 Max: 51.63
Current: 25.47
14.98
51.63
Current Ratio 1.12
MCK's Current Ratio is ranked lower than
83% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.60 vs. MCK: 1.12 )
Ranked among companies with meaningful Current Ratio only.
MCK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.25 Max: 1.71
Current: 1.12
1.07
1.71
Quick Ratio 0.70
MCK's Quick Ratio is ranked lower than
83% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.14 vs. MCK: 0.70 )
Ranked among companies with meaningful Quick Ratio only.
MCK' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 0.65 Max: 0.88
Current: 0.7
0.52
0.88
Days Inventory 31.18
MCK's Days Inventory is ranked higher than
64% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 41.06 vs. MCK: 31.18 )
Ranked among companies with meaningful Days Inventory only.
MCK' s Days Inventory Range Over the Past 10 Years
Min: 30.05  Med: 31.71 Max: 33.37
Current: 31.18
30.05
33.37
Days Sales Outstanding 34.40
MCK's Days Sales Outstanding is ranked higher than
77% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 62.35 vs. MCK: 34.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
MCK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.03  Med: 26.68 Max: 34.4
Current: 34.4
22.03
34.4
Days Payable 61.95
MCK's Days Payable is ranked lower than
58% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 82.92 vs. MCK: 61.95 )
Ranked among companies with meaningful Days Payable only.
MCK' s Days Payable Range Over the Past 10 Years
Min: 44.77  Med: 50.92 Max: 61.95
Current: 61.95
44.77
61.95

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.78
MCK's Dividend Yield is ranked lower than
93% of the 54 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.94 vs. MCK: 0.78 )
Ranked among companies with meaningful Dividend Yield only.
MCK' s Dividend Yield Range Over the Past 10 Years
Min: 0.35  Med: 0.64 Max: 1.42
Current: 0.78
0.35
1.42
Dividend Payout 0.13
MCK's Dividend Payout is ranked higher than
85% of the 33 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.28 vs. MCK: 0.13 )
Ranked among companies with meaningful Dividend Payout only.
MCK' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.13 Max: 2
Current: 0.13
0.04
2
Dividend Growth (3y) 10.50
MCK's Dividend Growth (3y) is ranked lower than
62% of the 26 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.70 vs. MCK: 10.50 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MCK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -21.7  Med: 0 Max: 44.2
Current: 10.5
-21.7
44.2
Forward Dividend Yield 0.77
MCK's Forward Dividend Yield is ranked lower than
91% of the 54 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.09 vs. MCK: 0.77 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.12
MCK's Yield on cost (5-Year) is ranked lower than
100% of the 54 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.77 vs. MCK: 1.12 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MCK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.52  Med: 0.94 Max: 2.1
Current: 1.12
0.52
2.1
3-Year Average Share Buyback Ratio 0.30
MCK's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 33 Companies
in the Global Medical Distribution industry.

( Industry Median: -1.10 vs. MCK: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MCK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: 0.2 Max: 5.7
Current: 0.3
-45.6
5.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.66
MCK's Price/Projected FCF is ranked higher than
93% of the 30 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.38 vs. MCK: 0.66 )
Ranked among companies with meaningful Price/Projected FCF only.
MCK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.02 Max: 17.04
Current: 0.66
0.55
17.04
Price/DCF (Earnings Based) 0.87
MCK's Price/DCF (Earnings Based) is ranked higher than
90% of the 10 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.43 vs. MCK: 0.87 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.90
MCK's Price/Median PS Value is ranked higher than
66% of the 44 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.98 vs. MCK: 0.90 )
Ranked among companies with meaningful Price/Median PS Value only.
MCK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 0.98 Max: 3.43
Current: 0.9
0.48
3.43
Price/Peter Lynch Fair Value 0.99
MCK's Price/Peter Lynch Fair Value is ranked higher than
80% of the 15 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.46 vs. MCK: 0.99 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MCK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.34  Med: 1.2 Max: 72.67
Current: 0.99
0.34
72.67
Earnings Yield (Greenblatt) (%) 9.28
MCK's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.90 vs. MCK: 9.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MCK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.5  Med: 8.7 Max: 17.6
Current: 9.28
4.5
17.6
Forward Rate of Return (Yacktman) (%) 24.88
MCK's Forward Rate of Return (Yacktman) (%) is ranked higher than
79% of the 33 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.44 vs. MCK: 24.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MCK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -14.6  Med: 20.1 Max: 94.3
Current: 24.88
-14.6
94.3

More Statistics

Revenue (TTM) (Mil) $194,267
EPS (TTM) $ 8.34
Beta0.94
Short Percentage of Float1.73%
52-Week Range $114.53 - 202.20
Shares Outstanding (Mil)226.09

Analyst Estimate

Mar17 Mar18 Mar19
Revenue (Mil $) 194,174 198,367 197,184
EPS ($) 12.55 12.78 14.16
EPS w/o NRI ($) 12.55 12.78 14.16
EPS Growth Rate
(3Y to 5Y Estimate)
9.59%
Dividends Per Share ($) 1.07 1.07 1.22
» More Articles for MCK

Headlines

Articles On GuruFocus.com
Analysis of AmerisourceBergen's Dividend Increase Nov 17 2016 
McKesson Falls and Recovers, but Still Undervalued? Nov 11 2016 
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
Why Cardinal Health Is My Favorite Health Care Stock Nov 01 2016 
12 Ways to Protect Yourself in Case the Company or Market Craters Oct 31 2016 
Guru Pain Is Your Gain in McKesson Oct 31 2016 
The Moat Stays Strong, Even If the Listing Is Gone Oct 24 2016 
Sometimes It Is Good to Buy the Biggest. But Should You Buy the Biggest Health Care Distribution Bus Jul 29 2016 
Mario Gabelli Comments on McKesson Corp Jul 26 2016 
Mario Gabelli Comments on McKesson Corp Jul 25 2016 

More From Other Websites
ETFs with exposure to McKesson Corp. : December 2, 2016 Dec 02 2016
Is General Dynamics Corporation (GD) A Good Stock To Buy? Nov 28 2016
Vulcan Value Partners Talks Oracle (ORCL)’s Value, Plus New Positions in McKesson (MCK), Qorvo... Nov 26 2016
Hedge Funds Are Dumping Aetna Inc. (AET) Nov 25 2016
Credit Suisse Cuts McKesson Shares To Underperform Nov 23 2016
McKesson downgraded by Credit Suisse Nov 23 2016
Andrew Left: Dump Mallinckrodt Nov 16 2016
McKesson Falls and Recovers, but Is It Still Undervalued? Nov 11 2016
Post Earnings Coverage as AmerisourceBergen Q4 Bottomline Outperformed Projections Nov 11 2016
Post Earnings Coverage as Cardinal Health Revenue Up 14% Nov 09 2016
CVS Health Dives On Sales Miss, Earnings Guidance; Walgreens Falls Nov 08 2016
NKE, AGN, NFLX: Jim Cramer's Views Nov 07 2016
Drug Wholesalers Feel Pricing Heat (MCK, ABC) Nov 06 2016
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016
The path of the economy depends on this election Nov 04 2016
Drugmakers under fire for possible U.S. price fixing Nov 03 2016
Top 5 medical distributors with good fundamentals : November 3, 2016 Nov 03 2016
Moving Average Crossover Alert: McKesson (MCK) Nov 03 2016
MCKESSON CORP Financials Nov 02 2016
Why Cardinal Health Is My Favorite Health Care Stock Nov 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)